Untreated HCV genotype 1 infection: Ledipasvir and Sofosbuvir as a fixed-dose combination highly effective


In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor Sofosbuvir and the NS5A inhibitor Ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepatitis C virus ( HCV ) genotype 1 infection.

Researchers have conducted a phase 3, open-label study involving previously untreated patients with chronic HCV genotype 1 infection.
Patients were randomly assigned in a 1:1:1:1 ratio to receive Ledipasvir and Sofosbuvir in a fixed-dose combination tablet once daily for 12 weeks, Ledipasvir - Sofosbuvir plus Ribavirin for 12 weeks, Ledipasvir -Sofosbuvir for 24 weeks, or Ledipasvir - Sofosbuvir plus Ribavirin for 24 weeks.

The primary endpoint was a sustained virologic response at 12 weeks after the end of therapy.

Of the 865 patients who underwent randomization and were treated, 16% had cirrhosis, 12% were black, and 67% had HCV genotype 1a infection.

The rates of sustained virologic response were 99% ( 95% confidence interval [CI], 96 to 100 ) in the group that received 12 weeks of Ledipasvir - Sofosbuvir; 97% ( 95% CI, 94 to 99 ) in the group that received 12 weeks of Ledipasvir - Sofosbuvir plus Ribavirin; 98% ( 95% CI, 95 to 99 ) in the group that received 24 weeks of Ledipasvir - Sofosbuvir; and 99% ( 95% CI, 97 to 100 ) in the group that received 24 weeks of Ledipasvir - Sofosbuvir plus Ribavirin.

No patient in either 12-week group discontinued Ledipasvir - Sofosbuvir owing to an adverse event.

The most common adverse events were fatigue, headache, insomnia, and nausea.

In conclusion, once-daily Ledipasvir - Sofosbuvir with or without Ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection. ( Xagena )

Afdhal N et al, NEJM 2014; Epub ahead of print

XagenaMedicine_2014



Indietro

Altri articoli

The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir )...


Although direct-acting antiviral ( DAA ) therapies for chronic hepatitis C virus ( HCV ) infection have demonstrated high rates...


The European Commission ( EC ) has granted marketing authorization for Vosevi ( Sofosbuvir 400mg / Velpatasvir 100mg / Voxilaprevir...



Interim results from one of the ongoing phase II studies of RG-101 for the treatment of hepatitis C virus infection...


A hepatitis C ( HCV ) drug currently under investigation, ABT-493 and ABT-530, which is an all-oral once-daily antiviral treatment,...


Data has demonstrated that choosing a different combination of direct-acting antiviral ( DAA ) treatment for hepatitis C can eradicate...


The European Commission has granted marketing authorization for Epclusa ( Sofosbuvir 400 mg / Velpatasvir 100 mg ), the first...


Researchers have conducted a study to analyze how infection by hepatitis C virus ( HCV ) may influence the immunological...


< br>The European Commission ( EC ) has granted marketing authorizations for Abbvie's all-oral, short-course, Interferon-free treatment of Viekirax (...